<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Antiviral Therapy and Prophylaxis for Influenza in Children </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/119/4/852" />
      <meta content="/pediatrics/119/4/852.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Antiviral Therapy and Prophylaxis for Influenza in Children"
            name="DC.Title" />
      <meta content="10.1542/peds.2007-0224" name="DC.Identifier" />
      <meta content="2007-04-01" name="DC.Date" />
      <meta content="American Academy of Pediatrics" name="DC.Publisher" />
      <meta ca in Children"
            name="DC.Titleontent="Committee on Infectious Diseases" name="DC.Contributor" />
      <meta content="32.00" name="citation_collection_id" />
      <meta content="32.03" name="citation_collection_id" />
      <meta content="32.04" name="citation_collection_id" />
      <meta content="Pediatrics" name="citation_journal_title" />
      <meta content="Pediatrics" name="citation_journal_abbrev" />
      <meta content="0031-4005" name="citation_issn" />
      <meta content="1098-4275" name="citation_issn" />
      <meta content="Antiviral Therapy and Prophylaxis for Influenza in Children"
            name="citation_title" />
      <meta content="04/01/2007" name="citation_date" />
      <meta content="119" name="citation_volume" />
      <meta content="4" name="citation_issue" />
      <meta content="852" name="citation_firstpage" />
      <meta content="860" name="citation_lastpage" />
      <meta content="119/4/852" name="citation_id" />
      <meta content="119/4/852" name="citation_id_from_sass_path" />
      <meta content="pediatrics;119/4/852" name="citation_mjid" />
      <meta content="10.1542/peds.2007-0224" name="citation_doi" />
      <meta content="http://pediatrics.aappublications.org/content/119/4/852.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://pediatrics.aappublications.org/content/119/4/852.full"
            name="citation_fulltext_html_url" />
      <meta content="http://pediatrics.aappublications.org/content/119/4/852.full.pdf"
            name="citation_pdf_url" />
      <meta content="http://pediatrics.aappublications.org/content/119/4/852"
            name="citation_public_url" />
      <meta content="17403862" name="citation_pmid" />
      <meta name="citation_section" content="FROM THE AMERICAN ACADEMY OF PEDIATRICS" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/119/4/846.short" rel="prev" />
      <link href="/content/119/4/861.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/standard-designs/design2/main.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-journal-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-journal-sidebars.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-leaderboard.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-leaderboard.css" /><script type="text/javascript" id="session-d24903964e1">var callbackToken='57700C4F34602C4';</script><script type="text/javascript" id="session-d24903964e3">
                      var subCode='aapjournal_sub';
                    </script><script type="text/javascript" id="session-d24903964e5">
						var subScriptionType = 'this-site';
					</script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/shared/js/design/hw-design1.js"></script><script type="text/javascript" src="/local/js/hw-local-header-nav.js"></script><script type="text/javascri><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/shared/js/design/hw-design1.js"></script><script type="text/javascript" src="/local/js/pt" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/local/js/hw-local-content.js"></script><link rel="stylesheet" type="text/css" media="all" href="/site/css/global_styles.css" /><script type="text/javascript">
          
      	  
        
              var OAS_sitepage = 'pediatrics.aappublications.org/members';
          
    
      
      </script><script type="text/javascript" src="/publisher/js/ads-realmedia.js"></script><script type="text/javascript" src="/publisher/js/survey.js"></script><script type="text/javascript">var expdate='9999-12-31T23:59:59.999-08:00';</script><script type="text/javascript"
              src="http://www.aappublications.org/site/misc/renewal.js"></script></head>
   <body>
      <div class="hw-gen-page pagetype-content" id="pageid-content" itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <div id="header">
            
            <div class="heade-top"></div><a href="/">
               <img title="Pediatrics" width="960" height="92" id="main-logo"
                    src="/local/img/journal-logo-inner.gif" />
               <img title="Pediatrics" width="960" height="28" id="main-logo"
                    src="/local/img/sub-banner-inner.gif" />        
               </a>
            
            <p id="skip-link">
               <a href="#content-block">Skip to main page content</a>
               
            </p>
            
            <ul class="button-list header-buttons">
               <ul>
                  <li class="first">
                     <a href="/" title="Home">
                        <span>Home</span>
                        </a>
                     
                  </li>
                  <li>
                     <a href="/site/misc/about.xhtml" title="eArchive">
                        <span>About</span>
                        </a>
                     
                  </li>
                  <li>
                     <a href="/content/current" title="Current Issue">
                        <span>Current Issue</span>
                        </a>
                     
                  </li>
                  <li>
                     <a href="/site/aappolicy/index.xhtml" rel="external-nw" title="AAP Policy">
                        <span>AAP Policy</span>
                        </a>
                     
                  </li>
                  <li>
                     <a href="/content" title="eArchive">
                        <span>eArchives</span>
                        </a>
                     
                  </li>
                  <li>
                     <a href="/content/supplemental" title="Supplement">
                        <span>Supplements</span>
                        </a>
                     
                  </li>
                  <li>
                     <a href="/cgi/collection/" title="Collections">
                        <span>Collections</span>
                        </a>
                     
                  </li>
                  <li>
                     <a href="/letters" title="eLetters">
                        <span>eLetters</span>
                        </a>
                     
                  </li>
                  <li class="last">
                     <a href="/content/early/recent" title="Early Releases">
                        <span>Early Releases</span>
                        </a>
                     
                  </li>
                  <li>
                     <a href="/feedback" title="eArchive">
                        <span>Contact Us</span>
                        </a>
                     
                  </li>
               </ul>
            </ul>
            
            
            
            <div class="header-ac-elements">
               
               <div class="inst-branding">
                  
               </div>
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution: Nyu Medical Center</li>
                  </ul>           
                  
               </div> 
               
               
               
            </div>
            
            <div class="banner-ads">
               
               <ul>
                  <li class="position-1 no-ad hdr_left"><span>  </span></li>
               </ul>
               
            </div>
            
            <div class="bar">
               
               <div class="bar-inner"></div>
               
            </div>
            
         </div>
         <div id="leaderboard" class="leaderboard-ads">
            
            <ul>
               <li class="position-ad">
                  <script language="JavaScript" type="text/javascript">
            OAS_AD('Top');
          </script>
                  </li>
               <li class="position-top">
                  <a cla  <ul>
               <li class="position-ad">
                  <script language="JavaScript" typss="tower-ads-word" href="/site/misc/ad_disclaimer.xhtml">Advertising Disclaimer</a>          
                  
               </li>
            </ul>
            
         </div>
         <div class="leaderboard-clear sb-div"></div>
         <div id="content-block">
            <div id="before_resource_related_reaffirmation"
                 class="relmgr-relation related_reaffirmation">
               <p title="126 (3): 591">See original article: <a href="/content/126/3/591.short">
                     126 (3): 591</a>.
               </p>
            </div>
            <div id="before_resource_related_retirement"
                 class="relmgr-relation related_retirement">
               <p title="133 (5): e1479">See original article: <a href="/content/133/5/e1479.short">
                     133 (5): e1479</a>.
               </p>
            </div>
            <ul class="subject-headings last-child">
               <li>FROM THE AMERICAN ACADEMY OF PEDIATRICS</li>
            </ul><span class="series-title">
               
               </span><div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Antiviral Therapy and Prophylaxis for Influenza in Children</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="last" id="contrib-1"><span class="collab" id="collab-1">Committee on Infectious Diseases</span></li>
                  </ol>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-1" title="INTRODUCTION" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  <p id="p-1">Antiviral agents are available that are safe and effective for the treatment and prophylaxis of influenza virus infections
                     in children. The neuraminidase inhibitors (oseltamivir [Tamiflu] and zanamivir [Relenza]) are preferred agents because of
                     current widespread resistance to the adamantanes (amantadine [Symmetrel] and rimantadine [Flumadine]). Therapy should be provided
                     to children with influenza infection who are at high risk of severe infection and to children with moderate-to-severe influenza
                     infection who may benefit from a decrease in the duration of symptoms. Prophylaxis should be provided (1) to high-risk children
                     who have not yet received immunization and during the 2 weeks after immunization, (2) to unimmunized family members and health
                     care professionals with close contact with high-risk unimmunized children or infants who are younger than 6 months, and (3)
                     for control of influenza outbreaks in unimmunized staff and children in an institutional setting. Testing of current H5N1
                     avian influenza virus isolates, the potential agents of pandemic influenza, suggests susceptibility to oseltamivir and zanamivir.
                     Because no prospective data exist on the efficacy of these agents in humans for H5N1 strains, the dosage and duration of therapy
                     in adults and children may differ from those documented to be effective for epidemic influenza strains.
                  </p>
               </div><span class="kwd-group-title gen-title">Key Words:</span><ul class="kwd-group KWD">
                  <li class="kwd"><span><a class="kwd-search"
                           href="/search?fulltext=influenza&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">influenza</a></span></li>
                  <li class="kwd"><span><a class="kwd-search"
                           href="/search?fulltext=children&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">children</a></span></li>
                  <li class="kwd"><span><a class="kwd-search"
                           href="/search?fulltext=influenza+antiviral&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">influenza antiviral</a></span></li>
                  <li class="kwd"><span><a class="kwd-search"
                           href="/search?fulltext=oseltamivir&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">oseltamivir</a></span></li>
                  <li class="kwd"><span><a class="kwd-search"
                           href="/search?fulltext=zanamivir&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">zanamivir</a></span></li>
                  <li class="kwd"><span><a class="kwd-search"
                           href="/search?fulltext=amantadine&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">amantadine</a></span></li>
                  <li class="kwd"><span><a class="kwd-search"
                           href="/search?fulltext=rimantadine&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">rimantadine</a></span></li>
                  <li class="kwd"><span><a class="kwd-search"
                           href="/search?fulltext=ribavirin&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">ribavirin</a></span></li>
               </ul>
               <div class="section" id="sec-1">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-2" title="ANTIVIRAL DRUGS FOR EPIDEMIC AND PANDEMIC INFLUENZA"
                        class="next-section-link"><span>Next Section</span></a></div>
                  <h2>INTRODUCTION</h2>
                  <p id="p-2">Antiviral agents for treatment and prophylaxis of influenza are safe and effective in children. Annual immunization against
                     influenza is the preferred strategy for prevention of infection, but certain situations exist in which the use of antiviral
                     agents is beneficial.
                  </p>
                  <p id="p-3">The morbidity and mortality of epidemic influenza in unimmunized children is substantial, particularly in those younger than
                     2 years.<sup><a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>–<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a></sup> The purpose of this report is to offer guidance regarding antiviral treatment and prophylaxis to clinicians caring for children
                     during yearly influenza epidemics and to provide resources for information on antiviral treatment in the event of an influenza
                     pandemic, because no prospective human data currently exist on which to base recommendations for treatment of ing yearly influenza epidemics and to provide resources for information on antiviral treatment in the event of an influenza
                     pandemic, because no prospective human data currently exist on which to base recommendations for treatment nfections caused
                     by potential H5N1 pandemic influenza virus strains.
                  </p>
               </div>
               <div class="section" id="sec-2">
                  <div class="section-nav"><a href="#sec-1" title="INTRODUCTION" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-16" title="INDICATIONS FOR THERAPY AND PROPHYLAXIS"
                        class="next-section-link"><span>Next Section</span></a></div>
                  <h2>ANTIVIRAL DRUGS FOR EPIDEMIC AND PANDEMIC INFLUENZA</h2>
                  <p id="p-4">Two classes of antiviral medications are currently available for treatment or prophylaxis of influenza infections: neuraminidase
                     inhibitors (NAIs) (oseltamivir [Tamiflu; Roche Laboratories, Nutley, NJ] and zanamivir [Relenza; GlaxoSmithKline, Research
                     Triangle Park, NC]) and the adamantanes (amantadine [Symmetrel; Endo Pharmaceuticals, Chads Ford, PA] and rimantadine [Flumadine;
                     Forest Pharmaceuticals, St Louis, MO]). Guidelines for the use of these 4 antiviral agents are summarized in Table <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">1</a>. Little is currently known about the efficacy of antiviral agents against H5N1 strains of influenza A virus that may ultimately
                     cause an influenza pandemic. Current concerns about widespread resistance to the adamantanes limit the usefulness of this
                     class of agents for both epidemic strains and H5N1 strains of influenza A virus.
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="852/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="852/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>TABLE 1</strong></span> 
                        <p id="p-95" class="first-child">Dosing Recommendations for Antiviral Agents for Treatment and Prophylaxis of Influenza</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <p id="p-5">The NAIs block the action of influenza neuraminidase, an enzyme present on the viral envelope that provides for the efficient
                     release of progeny virion particles from the surface of an infected cell. The target of the adamantanes is the viral M2 matrix
                     protein, an ion-channel protein that spans the viral envelope's lipid bilayer and is required for viral uncoating. Detailed
                     reviews of antiviral therapy have been published recently.<sup><a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>–<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a></sup></p>
                  <p id="p-6">With all antiviral medications, treatment earlier in the course of infection is likely to offer maximum benefit. Treatment
                     starting as early as 12 hours after onset of symptoms has the greatest impact on disease resolution.<sup><a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a></sup> Most studies have been performed in otherwise healthy children who had symptoms for less than 48 hours, with the reported
                     improvement in outcomes being most profound in those children who were provided early therapy. Although study populations
                     may not accurately reflect the diverse patient population seen by health care professionals, the longer symptoms extend beyond
                     48 hours before starting treatment, the less likely the child will benefit from antiviral therapy.
                  </p>
                  <p id="p-7">The antiviral agents discussed below that are approved for treatment andnd beyond
                     48 hours before starting treatment, the less likely the child will benefit from antiviral therapy.
                  </p>
                  <p id="p-7">The antiviral /or prophylaxis of influenza are active only against
                     influenza viruses. Exposing children to antiviral therapy for noninfluenza infections results in unnecessary toxicity and
                     cost and may deplete the supply of antiviral agents. Testing for influenza is encouraged if available and expected to influence
                     clinical management, particularly at the onset of the influenza season.<sup><a id="xref-ref-5-2" class="xref-bibr" href="#ref-5">5</a></sup> The sensitivity and specificity of rapid diagnostic tests for influenza have been reviewed recently.<sup><a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a></sup></p>
                  <div id="sec-3" class="subsection">
                     <h3>NAIs</h3>
                     <div id="sec-4" class="subsection">
                        <h4>Background</h4>
                        <p id="p-8">There are 2 NAIs approved by the US Food and Drug Administration (FDA): oseltamivir and zanamivir. Oseltamivir is available
                           in tablet and liquid forms, but zanamivir is only available in an aerosol formulation.
                        </p>
                        <p id="p-9">Infection of the cell by influenza virus is initiated when viral hemagglutinin binds to sialic acid–containing glycoproteins
                           on the cell surface. After the virus enters the cell and viral proteins and nucleic acid subsequently are produced, new viral
                           particles assemble at the cell surface. The viral neuraminidase cleaves the virus from the host cell membrane attachment site,
                           thus freeing the virus to infect other cells. The NAI antiviral agents inhibit productive infection by preventing release
                           of infectious virus from host cell membranes and promote clumping of viral particles via binding to glycoproteins that are
                           present in respiratory mucus.<sup><a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>, <a id="xref-ref-12-2" class="xref-bibr" href="#ref-12">12</a></sup></p>
                     </div>
                     <div id="sec-5" class="subsection">
                        <h4>Oseltamivir Treatment</h4>
                        <p id="p-10">Oseltamivir has been investigated in a prospective, randomized, blinded, placebo-controlled study in children 1 to 12 years
                           of age.<sup><a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a></sup> A 5-day treatment course was associated with a median reduction in overall clinical illness of 36 hours and a reduction in
                           fever of 25 hours in oseltamivir-treated children compared with placebo recipients. Furthermore, the incidence of acute otitis
                           media (assessed by tympanometry and physician-prescribed antimicrobial therapy) was reduced by 44% compared with placebo recipients.
                           A significant decrease in viral shedding was also noted in treated children, with few children still shedding virus on day
                           4 of therapy. The most common adverse drug effects noted were gastrointestinal tract disturbances, with vomiting in 14% of
                           oseltamivir-treated children compared with 8% of children who were given placebo.
                        </p>
                        <p id="p-11">In studies of unimmunized children with asthma 6 to 12 years of age who received oseltamivir or placebo, no difference in
                           the median time to freedom from illness was demonstrated, but a significant improvement in pulmonary function was noted on
                           day 6 after treatment.<sup><a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a></sup> For oseltamivir-treated children whose therapy was started within 24 hours of onset, a more dramatic difference in alleviation
                           of all symptoms was noted, compared with those who were started on therapy after 24 to 48 hours of symptoms.
                children whose therapy was started within 24 hours of onset, a more dramatic difference in alleviation
                           of all symptoms was noted, compared with those who were started on therapy         </p>
                        <p id="p-12">Although earlier therapy may lead to a more profound treatment effect, it is also possible that earlier treatment may impair
                           the host immunologic response to influenza infection. An impaired immune response could leave the host susceptible on reexposure
                           to the virus, as has been reported in 2 children with influenza B virus infections.<sup><a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a></sup></p>
                        <p id="p-13">Oseltamivir is not approved for therapy in children younger than 12 months because of concerns of central nervous system (CNS)
                           toxicity seen in infant rats.<sup><a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a></sup> Limited data on safety and efficacy of oseltamivir exist in this young age group, although no specific drug-attributable
                           toxicities have been observed to date.<sup><a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>, <a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a></sup></p>
                        <p id="p-14">Oseltamivir may be taken with or without food and is eliminated entirely by glomerular filtration and tubular secretion. The
                           dose of oseltamivir should be decreased by 50% for children with decreased renal function associated with a creatinine clearance
                           of between 10 and 30 mL/minute.
                        </p>
                        <p id="p-15">Unpublished safety data on oseltamivir were recently reviewed by the FDA on the basis of reports of neuropsychiatric events
                           associated with patients treated for influenza with oseltamivir (<a href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_09_01_Tamiflu%20AE%20Review%202006%20Redacted_D060309_092.pdf">www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_09_01_Tamiflu%20AE%20Review%202006%20Redacted_D060309_092.pdf</a>). Although 92%of the most recent cases were reported from Japan, a country with approximately 4 times more courses of oseltamivir
                           prescribed than in the United States, package labeling was changed in the United States in 2006 to alert physicians to the
                           possibility of these rare and unusual clinical findings. Accurate data on the incidence of these events are not available,
                           but they seem to be in the range of 1 in 10000 to 100000 treatment courses. On the basis of the FDA review, it is not known
                           whether the spontaneous reports of neuropsychiatric behavior reflect a true adverse event caused by oseltamivir, perhaps with
                           a greater incidence in populations with a certain genetic background; a result of CNS infection caused by influenza virus;
                           or a combination of both drug and virus in the CNS. There are no reports of neuropsychiatric events in adults or children
                           receiving oseltamivir prophylaxis for influenza infection.
                        </p>
                     </div>
                     <div id="sec-6" class="subsection">
                        <h4>Zanamivir Treatment</h4>
                        <p id="p-16">Zanamivir is administered by aerosol twice daily for 5 days. In a study of children 4 to 12 years of age, the mean duration
                           of symptomatic illness was reduced by 1.25 days in children who received zanamivir, compared with those who received placebo.<sup><a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a></sup> In 3 trials in subjects 12 years and older, zanamivir treatment decreased symptoms by 1 to 2.5 days in influenza-positive
                           subjects.<sup><a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>–<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a></sup> In a multicenter prospective study of subjects whose therapy was started within 30 hours of the onset of symptoms, resolution
                           of major symptoms occurred 3 days earlier in the treatment group compared with that in controls.<sup><a id="xref-ref-24-2" class="xref-bibr" href="#ref-24">24</a></sup></p>
                        <p id="p-17">Reported adverse effects in otherwise healthy children and adults were similar between those treated with zanamivir and those
                           given placebo. However, concerns by the FDA regarding bronchospasm and decreased pulmonary function after inhalation of zanamivir
                           in patients with underlying reactive airways disease, including asthma and chronic obstructive pulmonary disease, prompted
                           warnings about use of zanamivir in this population. Potential risks and benefits should be carefully weighed before treatment
                           of these children. Monitoring of respiratory function should be considered if treatment is given.<sup><a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a></sup></p>
                        <p id="p-18">Zanamivir is minimally absorbed from the respiratory tract mucosa. No dosing changes are required for renal failure.</p>
                     </div>
                     <div id="sec-7" class="subsection">
                        <h4>Prophylaxis With Oseltamivir and Zanamivir</h4>
                        <p id="p-19">Postexposure prophylaxis with oseltamivir has been reported in a multicenter study in North America and Europe for family
                           contacts who were at least 1 year of age after identification of a documented index case within the family.<sup><a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a></sup> In this setting, in which the index case was also treated with oseltamivir, the protective efficacy against proven influenza
                           for individual contacts was 68%.<sup><a id="xref-ref-26-2" class="xref-bibr" href="#ref-26">26</a></sup> In a similar multicenter study for household contacts 12 years and older, oseltamivir was 89% effective in the prevention
                           of laboratory-confirmed symptomatic influenza infection when used within 48 hours of contact with an index case who had not
                           been treated.<sup><a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a></sup> Adverse events reported in treated subjects in this study, including gastrointestinal tract symptoms, were not different
                           from those in controls.<sup><a id="xref-ref-27-2" class="xref-bibr" href="#ref-27">27</a></sup></p>
                        <p id="p-20">Zanamivir was investigated as postexposure prophylaxis for family members 5 years and older, at a dosage of 10 mg, inhaled
                           once daily for 10 days, with the index case also receiving treatment. After exposure to a virus-positive index case, the number
                           of families with a clinically symptomatic member decreased 72%.<sup><a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a></sup></p>
                     </div>
                     <div id="sec-8" class="subsection">
                        <h4>Antiviral Resistance</h4>
                        <p id="p-21">Development of resistance to NAIs while on therapy occurs less often than resistance to adamantanes.<sup><a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a></sup> In a multicenter study in the United States, only 5% of children who received oseltamivir therapy developed in vitro resistance
                           in influenza isolates cultured during therapy.<sup><a id="xref-ref-14-2" class="xref-bibr" href="#ref-14">14</a></sup> In contrast, a study from Japan documented resistance of 18% in isolates cultured from 50 oseltamivir-treated children.<sup><a id="xref-ref-12-3" class="xref-bibr" href="#ref-12">12</a>, <a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a></sup> Fortunately, oseltamivir-resistant isolates from children do not seem to be as capable of sustaining infection as wild-type
                           strains as assessed in animal models of influenza infection.<sup><a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>, <a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a></sup> However, when generated entirely in vitro, some mutants are just as capable of infectivity as the parent strain,<sup><a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a></sup> which indicates that the possibility still exists for the development and spread of oseltamivir-resistant strains among children.
                           Zanamivir resistance was not reported in the published large-scale clinical trials.
                        </p>
                     </div>
                  </div>
                  <div id="sec-9" class="subsection">
                     <h3>Adamantanes</h3>
                     <div id="sec-10" class="subsection">
                        <h4>Background</h4>
                        <p id="p-22">Amantadine and rimantadine are approved for children 12 months and older. Amantadine, the first antiviral agent available
                           against influenza, was approved by the FDA in 1966; rimantadine was approved in 1993. Antiviral activity is mediated by binding
                           these agents to the M2 protein ion channels on the viral envelope, preventing acidic conditions within the virus that are
                           required for uncoating and subsequent release of viral nucleic acid into the host cell.<sup><a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a></sup> Only influenza A virus contains the M2 protein. A different envelope protein that does not bind to the adamantanes provides
                           a similar function in influenza B virus; amantadine and rimantadine are not active against influenza B. The effectiveness
                           of adamantanes has been limited by the emergence of widespread resistance in H3N2 strains isolated in the 2005–2006 influenza
                           season.<sup><a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a></sup> Recommendations for adamantane antiviral use in subsequent years will be based on the resistance patterns documented in strains
                           circulating during those influenza seasons.
                        </p>
                     </div>
                     <div id="sec-11" class="subsection">
                        <h4>Amantadine Treatment</h4>
                        <p id="p-23">Placebo-controlled, randomized clinical trials have documented that amantadine treatment decreases the duration of fever and
                           other influenza-attributable symptoms in influenza caused by adamantane-susceptible strains by approximately 1 day in children
                           1 year and older.<sup><a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>–<a id="xref-ref-40-1" class="xref-bibr" href="#ref-40">40</a></sup> However, many of the earlier placebo-controlled studies that included children did not report age-specific response or adverse-event
                           rates. Adverse events have been most accurately assessed and reported in adults. The most commonly occurring (5%–10%) adverse
                           events are nausea, lightheadedness, and insomnia. Those that occur infrequently (1%–5%) include anxiety, nervousness, irritability,
                           dry mouth, headache, fatigue, and diarrhea.<sup><a id="xref-ref-41-1" class="xref-bibr" href="#ref-41">41</a></sup> The incidence of CNS adverse effects noted above is twofold higher in those taking amantadine than in those taking rimantadine.
                           Gastrointestinal adverse effects are equivalent between the 2 agents. These effects are dosage related and are usually mild,
                           resolving when the agent is discontinued. Serious adverse effects have been reported in adults and are often associated with
                           either high plasma drug concentrations in patients with renal insufficiency or in those with an underlying psychiatric or
                           seizure disorder.<sup><a id="xref-ref-42-1" class="xref-bibr" href="#ref-42">42</a></sup></p>
                        <p id="p-24">Although no prospective studies have been published on the treatment of children with encephalitis as a complication of influenza,
                           data on cerebrospinal fluid concentrations of amantadine suggest a high degree of cerebrospinal fluid penetration, with concentrations
                           that may provide antiviral activity.<sup><a id="xref-ref-43-1" class="xref-bibr" href="#ref-43">43</a></sup></p>
                        <p id="p-25">Amantadine is well absorbed orally and is excreted almost entirely by the kidneys with variable metabolism before elimination.
                           The dose should be decreased 50% in children with creatinine clearance between 30 and 50 mL/minute per 1.73 m<sup>2</sup>. Additional reductions are required for more profound renal failure.
                        </p>
                     </div>
                     <div id="sec-12" class="subsection">
                        <h4>Rimantadine Treatment</h4>
                        <p id="p-26">Rimantadine was evaluated in prospective studies of children using acetaminophen-treated controls between 1 and 12 years of
                           age<sup><a id="xref-ref-44-1" class="xref-bibr" href="#ref-44">44</a></sup> and 1 and 15 years of age.<sup><a id="xref-ref-45-1" class="xref-bibr" href="#ref-45">45</a></sup> In a study by Thompson et al,<sup><a id="xref-ref-44-2" class="xref-bibr" href="#ref-44">44</a></sup> no differences were recorded in the reduction of symptoms between the 2 groups, although the amount of virus shed was less
                           during the first 2 days of therapy for the treatment group. Of concern, the virus shed by those who continued to have positive
                           culture results on the fourth day of treatment was often resistant to rimantadine. Hall and colleagues<sup><a id="xref-ref-45-2" class="xref-bibr" href="#ref-45">45</a></sup> noted a significant reduction in severity of disease, including fever. However, a high rate of rimantadine resistance occurred
                           in treated children, with almost half of the strains noted to be resistant when isolated from children who were still shedding
                           virus at the end of the 7-day treatment course. In addition, it is concerning that rimantadine-treated children were more
                           likely to be shedding virus at the end of therapy than were controls. No differences in adverse-event rates were noted between
                           children treated with rimantadine and those treated with acetaminophen. In controlled studies in adults, no drug-attributable
                           adverse effects occurred in more than 5% of the study subjects, with the most commonly reported events being insomnia and
                           dizziness.<sup><a id="xref-ref-46-1" class="xref-bibr" href="#ref-46">46</a></sup></p>
                        <p id="p-27">Rimantadine is also well absorbed orally but, unlike amantadine, undergoes extensive hepatic metabolism with subsequent renal
                           elimination. Dose adjustment should be made for severe hepatic dysfunction or renal failure.
                        </p>
                     </div>
                     <div id="sec-13" class="subsection">
                        <h4>Prophylaxis With Amantadine and Rimantadine</h4>
                        <p id="p-28">Early studies on the prevention of influenza with amantadine were conducted in home or institutional settings during the influenza
                           season using prospective, double-blind trial designs and documented a statistically significant benefit by reducing the attack
                           rate of influenza A.<sup><a id="xref-ref-47-1" class="xref-bibr" href="#ref-47">47</a>–<a id="xref-ref-50-1" class="xref-bibr" href="#ref-50">50</a></sup> However, as with the early amantadine treatment studies, age-specific data are lacking.
              te of influenza A.<sup><a id="xref-ref-47-1          </p>
                        <p id="p-29">Studies on the use of rimantadine as prophylaxis for children within families were conducted during influenza seasons in which
                           the predominant circulating strains were H1N1<sup><a id="xref-ref-51-1" class="xref-bibr" href="#ref-51">51</a></sup> and H3N2.<sup><a id="xref-ref-52-1" class="xref-bibr" href="#ref-52">52</a></sup> In both studies, prophylaxis reduced the number of symptomatic influenza cases in children relative to an attack rate of
                           15% to 20% among placebo recipients. Prophylaxis in children also reduced the number of cases of symptomatic influenza in
                           adult family members. Of note, cases of asymptomatic influenza infection as documented by throat culture or fourfold increase
                           in influenza antibody titers did occur in a small number of children who received rimantadine prophylaxis.
                        </p>
                     </div>
                     <div id="sec-14" class="subsection">
                        <h4>Antiviral Resistance</h4>
                        <p id="p-30">Amantadine or rimantadine resistance develops in approximately one third of patients who receive antiviral therapy.<sup><a id="xref-ref-53-1" class="xref-bibr" href="#ref-53">53</a></sup> The development of resistance has implications for therapeutic failure for (1) the child, if resistance develops early in
                           therapy, (2) household or close contacts, because resistance in the index case determines which therapy is likely to be effective
                           in those exposed to the index case, and (3) communities, in which resistance may be so widespread to a particular agent that
                           empiric therapy with that agent may no longer be recommended.
                        </p>
                        <p id="p-31">Resistance to adamantanes occurs rapidly, often within the first 3 days of therapy. Mutations lead to structural changes at
                           predictable, specific sites on the M2 protein. These changes are relatively stable, with little reversion to wild-type susceptible
                           virus after stopping the adamantane. Appreciable differences in virulence or transmissibility between resistant and susceptible
                           viruses have not been noted.
                        </p>
                        <p id="p-32">In a recent study, nasal swabs, nasal aspirates, or throat cultures were obtained from hospitalized children before, during,
                           and after a 3- to 5-day course of amantadine, and 80% of isolates from treated children demonstrated amantadine resistance.<sup><a id="xref-ref-54-1" class="xref-bibr" href="#ref-54">54</a></sup> Shedding of resistant strains was not associated with persistent or relapsing clinical disease, which is felt to reflect
                           an adequate host immunologic response that develops as resistant strains are emerging. For the high-risk child with a poor
                           immunologic response to infection, persistent disease or relapse is a concern.
                        </p>
                        <p id="p-33">Close contacts of an amantadine- or rimantadine-treated child who subsequently develop influenza infection are at high risk
                           of infection caused by an adamantane-resistant influenza virus. If such patients require treatment or prophylaxis, an NAI
                           should be used. During the 2005–2006 influenza season, data collected on widespread resistance to adamantanes in circulating
                           influenza A strains in the United States led the Centers for Disease Control and Prevention to recommend against the use of
                           these agents for either treatment or prophylaxis of influenza A infections.<sup><a id="xref-ref-55-1" class="xref-bibr" href="#ref-55">55</a></sup></p>
                     </div>
                  </div>
                  <div id="sec-15" cl             these agents for either treatment or prophylaxis of influenza A infections.<sup><a id="xref-ref-55-1" class="xref-bibr" href="#ref-55">55</a></sup></p>
                     </div>
    ass="subsection">
                     <h3>Ribavirin</h3>
                     <p id="p-34">Ribavirin has in vitro activity against influenza virus but is not currently approved for treatment of influenza infection.
                        Limited studies have been performed with aerosolized ribavirin in the treatment of influenza in children.<sup><a id="xref-ref-56-1" class="xref-bibr" href="#ref-56">56</a></sup> For life-threatening influenza infection requiring parenteral therapy, intravenous ribavirin may be obtained as an investigational
                        product through the FDA, as supplied by the manufacturer. No prospective, controlled data currently exist on the safety or
                        efficacy of parenteral ribavirin for severe, invasive influenza infection, although limited data on pharmacokinetics of parenteral
                        ribavirin exist for adults.<sup><a id="xref-ref-57-1" class="xref-bibr" href="#ref-57">57</a></sup></p>
                  </div>
               </div>
               <div class="section" id="sec-16">
                  <div class="section-nav"><a href="#sec-2" title="ANTIVIRAL DRUGS FOR EPIDEMIC AND PANDEMIC INFLUENZA"
                        class="prev-section-link"><span>Previous Section</span></a><a href="#sec-19" title="ANTIVIRAL THERAPY IN PANDEMIC INFLUENZA"
                        class="next-section-link"><span>Next Section</span></a></div>
                  <h2>INDICATIONS FOR THERAPY AND PROPHYLAXIS</h2>
                  <div id="sec-17" class="subsection">
                     <h3>Therapy</h3>
                     <ul class="list-unord" id="list-1">
                        <li id="list-item-1">
                           <p id="p-36">Influenza infection of any severity in high-risk children (see Appendix) regardless of immunization status</p>
                        </li>
                        <li id="list-item-2">
                           <p id="p-37">Any otherwise healthy child with moderate-to-severe influenza infection who may benefit from the decrease in duration of clinical
                              symptoms documented to occur with therapy
                           </p>
                        </li>
                     </ul>
                  </div>
                  <div id="sec-18" class="subsection">
                     <h3>Prophylaxis</h3>
                     <ul class="list-unord" id="list-2">
                        <li id="list-item-3">
                           <p id="p-39">High-risk children during the 2 weeks after influenza immunization, if influenza is active in the community</p>
                        </li>
                        <li id="list-item-4">
                           <p id="p-40">High-risk children for whom influenza vaccine is contraindicated</p>
                        </li>
                        <li id="list-item-5">
                           <p id="p-41">Family members or health care providers who are unimmunized and are likely to have ongoing, close exposure to (1) high-risk,
                              unimmunized children or (2) infants who are younger than 6 months
                           </p>
                        </li>
                        <li id="list-item-6">
                           <p id="p-42">Control of influenza outbreaks for unimmunized staff and children in a closed institutional setting with high-risk pediatric
                              residents (eg, extended-care facilities)
                           </p>
                        </li>
                        <li id="list-item-7">
                           <p id="p-43">As a supplement to immunization among high-risk children</p>
                        </li>
                        <li id="list-item-8">
                           <p id="p-44">Postexposure prophylaxis in a family setting</p>
                        </li>
                        <li id="list-item-9">
                           <p id="p-45">High-risk children and their family members and close contacts, as well as health care workers, when circulating strains of
                              influenza virus in the community are not matched with vaccine strains
                           </p>
                        </li>
                     </ul>
                  </div>
               </div>
               <div class="section" id="sec-19">
                  <div class="section-nav"><a href="#sec-16" title="INDICATIONS FOR THERAPY AND PROPHYLAXIS"
                        class="prev-section-link"><span>Previous Section</span></a><a href="#sec-20" title="Committee on Infectious Diseases, 2006–2007"
                        class="next-section-link"><span>Next Section</span></a></div>
                  <h2>ANTIVIRAL THERAPY IN PANDEMIC INFLUENZA</h2>
                  <p id="p-46">Antiviral therapy may play a major role in both treatment and prophylaxis during a pandemic.<sup><a id="xref-ref-58-1" class="xref-bibr" href="#ref-58">58</a>, <a id="xref-ref-59-1" class="xref-bibr" href="#ref-59">59</a></sup> Pandemic influenza is likely to occur sometime within the next decade. Recent observations document the spread of an epidemic
                     of H5N1 strain of avian influenza A virus in both wild and domestic bird species from southeast Asia to Indonesia, Europe,
                     and Africa, with further spread felt likely to occur. As of October 16, 2006, 256 adult and pediatric cases of H5N1 influenza
                     infection have been documented worldwide, associated with a mortality rate of 59%.<sup><a id="xref-ref-60-1" class="xref-bibr" href="#ref-60">60</a></sup> These infections have occurred most often in those with close, direct contact with poultry. Efficient transmission of the
                     virus between humans, an event that is required before a human pandemic can occur, has not been documented to date with any
                     of the currently identified H5N1 strains.
                  </p>
                  <p id="p-47">Intense planning for the possibility of an influenza pandemic with a virulent strain of H5N1 or another influenza virus subtype
                     is ongoing at international, national, state, and local levels. The American Academy of Pediatrics and other professional
                     organizations and stakeholders have had important input into the Pandemic Influenza Strategic Plan of the US Department of
                     Health and Human Services, which was released in late 2005.<sup><a id="xref-ref-61-1" class="xref-bibr" href="#ref-61">61</a></sup> Interim priorities for antiviral therapy and vaccine are included as part of the plan and reflect a need to treat and protect
                     those most at risk of severe and fatal influenza and to preserve critical societal infrastructure (eg, law enforcement, medical
                     facilities, government). Efforts are currently underway to stockpile adequate supplies of antiviral drugs to address both
                     health care and societal requirements. The Strategic National Stockpile currently includes oseltamivir and rimantadine. Although
                     most strains of H5N1 are susceptible only to the NAIs, some are susceptible to the adamantanes. The dose and duration of therapy
                     for H5N1 infections may be different from those for currently circulating H3N2 or H1N1 infections. In the case of a pandemic,
                     the Centers for Disease Control and Prevention, the American Academy of Pediatrics, and state and local health departments
                     will provide current recommendations for therapy and prophylaxis.
                  </p>
               </div>
               <div class="section" id="sec-20">
                  <div class="section-nav"><a href="#sec-19" title="ANTIVIRAL THERAPY IN PANDEMIC INFLUENZA"
                        class="prev-section-link"><span>Previous Section</span></a><a href="#sec-21" title="Liaisons" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Committee on Infectious Diseases, 2006–2007</h2>
                  <p id="p-48">Joseph A. Bocchini, Jr, MD, Chairperson</p>
                  <p id="p-49">Robert S. Baltimore, MD</p>
                  <p id="p-50">Henry H. Bernstein, DO</p>
                  <p id="p-51">John S. Bradley, MD</p>
                  <p id="p-52">Michael T. Brady, MD</p>
                  <p id="p-53">Penelope H. Dennehy, MD</p>
                  <p id="p-54">Margaret C. Fisher, MD</p>
                  <p id="p-55">Robert W. Frenck, Jr, MD</p>
                  <p id="p-56">David W. Kimberlin, MD</p>
                  <p id="p-57">Sarah S. Long, MD</p>
                  <p id="p-58">Julia A. McMillan, MD</p>
                  <p id="p-59">Lorry G. Rubin, MD</p>
               </div>
               <div class="section" id="sec-21">
                  <div class="section-nav"><a href="#sec-20" title="Committee on Infectious Diseases, 2006–2007"
                        class="prev-section-link"><span>Previous Section</span></a><a href="#sec-22" title="Ex Officio" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Liaisons</h2>
                  <p id="p-60">Richard D. Clover, MD</p>
                  <p id="p-61">American Academy of Family Physicians</p>
                  <p id="p-62">Marc A. Fischer, MD</p>
                  <p id="p-63">Centers for Disease Control and Prevention</p>
                  <p id="p-64">Richard L. Gorman, MD</p>
                  <p id="p-65">National Institutes of Health</p>
                  <p id="p-66">R. Douglas Pratt, MD</p>
                  <p id="p-67">Food and Drug Administration</p>
                  <p id="p-68">Anne Schuchat, MD</p>
                  <p id="p-69">Centers for Disease Control and Prevention</p>
                  <p id="p-70">Benjamin Schwartz, MD</p>
                  <p id="p-71">National Vaccine Program Office</p>
                  <p id="p-72">Jeffrey R. Starke, MD</p>
                  <p id="p-73">American Thoracic Society</p>
                  <p id="p-74">Jack Swanson, MD</p>
                  <p id="p-75">Practice Action Group</p>
               </div>
               <div class="section" id="sec-22">
                  <div class="section-nav"><a href="#sec-21" title="Liaisons" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-23" title="Consultant" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Ex Officio</h2>
                  <p id="p-76">Larry K. Pickering, MD</p>
                  <p id="p-77"><em>Red Book</em> Editor
                  </p>
                  <p id="p-78">Carol J. Baker, MD</p>
                  <p id="p-79"><em>Red Book</em> Associate Editor
                  </p>
               </div>
               <div class="section" id="sec-23">
                  <div class="section-nav"><a href="#sec-22" title="Ex Officio" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-24" title="Staff" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Consultant</h2>
                  <p id="p-80">Edgar O. Ledbetter, MD</p>
               </div>
               <div class="section" id="sec-24">
                  <div class="section-nav"><a href="#sec-23" title="Consultant" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-25"
                        title="APPENDIX: INFANTS AND CHILDREN AT HIGH RISK OF COMPLICATIONS FROM INFLUENZA INCLUDE THOSE WITH:"
                        class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Staff</h2>
                  <p id="p-81">Alison Siwek, MPH</p>
               </div>
               <div class="section" id="sec-25">
                  <div class="section-nav"><a href="#sec-24" title="Staff" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>APPENDIX: INFANTS AND CHILDREN AT HIGH RISK OF COMPLICATIONS FROM INFLUENZA INCLUDE THOSE WITH:</h2>
                  <ul class="list-unord" id="list-3">
                     <li id="list-item-10">
                        <p id="p-83">Ages between 6 and 24 months (no antiviral agent is currently approved for infants younger than 12 months)</p>
                     </li>
                     <li id="list-item-11">
                        <p id="p-84">Asthma or other chronic pulmonary diseases such as cystic fibrosis</p>
                     </li>
                     <li id="list-item-12">
                        <p id="p-85">Hemodynamically significant cardiac disease</p>
                     </li>
                     <li id="list-item-13">
                        <p id="p-86">Immunosuppressive disorders or therapy</p>
                     </li>
                     <li id="list-item-14">
                        <p id="p-87">HIV infection</p>
                     </li>
                     <li id="list-item-15">
                        <p id="p-88">Sickle cell anemia and other hemoglobinopathies</p>
                     </li>
                     <li id="list-item-16">
                        <p id="p-89">Diseases requiring long-term aspirin therapy, such as rheumatoid arthritis or Kawasaki disease</p>
                     </li>
                     <li id="list-item-17">
                        <p id="p-90">Chronic renal dysfunction</p>
                     </li>
                     <li id="list-item-18">
                        <p id="p-91">Chronic metabolic disease such as diabetes mellitus</p>
                     </li>
                     <li id="list-item-19">
                        <p id="p-92">Neuromuscular disorders, seizure disorders, or cognitive dysfunction that may compromise the handling of respiratory secretions</p>
                     </li>
                  </ul>
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-25"
                        title="APPENDIX: INFANTS AND CHILDREN AT HIGH RISK OF COMPLICATIONS FROM INFLUENZA INCLUDE THOSE WITH:"
                        class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="REFERENCES" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn fn-group-arthw-misc" id="fn-1">
                        <p id="p-93">All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed,
                           revised, or retired at or before that time.
                        </p>
                     </li>
                     <li class="fn fn-group-arthw-misc" id="fn-2">
                        <p id="p-94">The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations,
                           taking into account individual circumstances, may be appropriate.
                        </p>
                     </li>
                  </ul>
               </div><span class="rsna-kwd-group ABR"><span class="rsna-kwd">NAI—neuraminidase inhibitor</span><span class="rsna-kwd-sep"> • </span><span class="rsna-kwd">FDA—Food and Drug Administration</span><span class="rsna-kwd-sep"> • </span><span class="rsna-kwd">CNS—central nervous system</span></span><div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>REFERENCES</h2>
                  <ol class="cit-list">
                     <li><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1 in text"
                           id="ref-1">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.1"
                             data-doi="10.1542/peds.110.6.1246">
                           <div class="cit-metadata"><cite>American Academy of Pediatrics, Committee on Infectious Diseases. Reduction of the influenza burden in children.
                                 <span class="cit-source">Pediatrics.</span><span class="cit-pub-date">2002<  <div class="cit-metadata"><cite>American Academy/span>;<span class="cit-vol">110</span>
                                 :<span class="cit-fpage">1246</span>–
                                 1252</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=pediatrics&amp;resid=110/6/1246"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.2"
                             data-doi="10.1056/NEJM200001273420402">
                           <div class="cit-metadata"><cite>Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants
                                 and young children.
                                 <span class="cit-source">N Engl J Med.</span><span class="cit-pub-date">2000</span>;<span class="cit-vol">342</span>
                                 :<span class="cit-fpage">232</span>–
                                 239</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM200001273420402&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10648764&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000084941000002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.3"
                             data-doi="10.1056/NEJM200001273420401">
                           <div class="cit-metadata"><cite>Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits,
                                 and courses of antibiotics in children.
                                 <span class="cit-source">N Engl J Med.</span><span class="cit-pub-date">2000</span>;<span class="cit-vol">342</span>
                                 :<span class="cit-fpage">225</span>–
                                 231</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM200001273420401&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10648763&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000084941000001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.4"
                             data-doi="10.1056/NEJMoa051721">
                           <div class="cit-metadata"><cite>Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003–2004.
                                 <span class="cit-source">N Engl J Med.</span><span class="cit-pub-date">2005</span>;<span class="cit-vol">353</span>
                                 :<span class="cit-fpage">2559</span>–
                                 2567</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa051721&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16354892&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000233926500005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5 in text"
                           id="ref-5">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.5"
                             data-doi="10.1056/NEJMoa054869">
                           <div class="cit-metadata"><cite>Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children.
                                 <span class="cit-source">N Engl J Med.</span><span class="cit-pub-date">2006</span>;<span class="cit-vol">355</span>
                                 :<span class="cit-fpage">31</span>–
                                 40</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa054869&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16822994&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000238783200005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6 in text"
                           id="ref-6">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.6"
                             data-doi="10.1046/j.1469-0691.2003.00564.x">
                           <div class="cit-metadata"><cite>Oxford JS, Bossuyt S, Balasingam S, Mann A, Novelli P, Lambkin R. Treatment of epidemic and pandemic influenza with neuraminidase
                                 and M2 proton channel inhibitors.
                                 <span class="cit-source">Clin Microbiol Infect.</span><span class="cit-pub-date">2003</span>;<span class="cit-vol">9</span>
                                 :<span class="cit-fpage">1</span>–
                                 14</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1469-0691.2003.00564.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12691538&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000180966400001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.7"
                             data-doi="10.1136/bmj.326.7401.1235">
                           <div class="cit-metadata"><cite>Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment
                                 and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.
                                 <span class="cit-source">BMJ.</span><span class="cit-pub-date">2003</span>;<span class="cit-vol">326</span>
                                 :<span class="cit-fpage">1235</span></cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=326/7401/1235"
                                 class="cit-ref-spri                       :<span class="cit-fpage">1235</span></cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&ampnkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.8">
                           <div class="cit-metadata"><cite>Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention
                                 and treatment of influenza A and B.
                                 <span class="cit-source">Health Technol Assess.</span><span class="cit-pub-date">2003</span>;<span class="cit-vol">7:iii–iv, xi–xiii</span>
                                 ,<span class="cit-fpage">1</span>–
                                 170</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=12583822&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9 in text"
                           id="ref-9">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.9"
                             data-doi="10.1097/00006454-200302000-00015">
                           <div class="cit-metadata"><cite>Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment
                                 for influenza.
                                 <span class="cit-source">Pediatr Infect Dis J.</span><span class="cit-pub-date">2003</span>;<span class="cit-vol">22</span>
                                 :<span class="cit-fpage">164</span>–
                                 177</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/00006454-200302000-00015&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12586981&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000181062700013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10 in text"
                           id="ref-10">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.10">
                           <div class="cit-metadata"><cite>Matheson NJ, Symmonds-Abrahams M, Sheikh A, Shepperd S, Harnden A. Neuraminidase inhibitors for preventing and treating influenza
                                 in children.
                                 <span class="cit-source">Cochrane Database Syst Rev.</span><span class="cit-pub-date">2003</span>;<span class="cit-vol">(3)</span>
                                 :CD002744</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.11"
                             data-doi="10.2165/00003495-200464180-00003">
                           <div class="cit-metadata"><cite>Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review.
                                 <span class="cit-source">Drugs.</span><span class="cit-pub-date">2004</span>;<span class="cit-vol">64</span>
                                 :<span class="cit-fpage">2031</span>–
                                 2046</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2165/00003495-200464180-00003&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15341496&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000224166700003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12 in text"
                           id="ref-12">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.12"
                             data-doi="10.1016/S0140-6736(04)16947-X">
                           <div class="cit-metadata"><cite>Moscona A. Oseltamivir-resistant influenza?
                                 <span class="cit-source">Lancet.</span><span class="cit-pub-date">2004</span>;<span class="cit-vol">364</span>
                                 :<span class="cit-fpage">733</span>–
                                 734</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(04)16947-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15337382&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000223569600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13 in text"
                           id="ref-13">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.13"
                             data-doi="10.1093/jac/dkg007">
                           <div class="cit-metadata"><cite>Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment.
                                 <span class="cit-source">J Antimicrob Chemother.</span><span class="cit-pub-date">2003</span>;<span class="cit-vol">51</span>
                                 :<span class="cit-fpage">123</span>–
                                 129</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jac&amp;resid=51/1/123"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14 in text"
                           id="ref-14">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.14"
                             data-doi="10.1097/00006454-200102000-00002">
                           <div class="cit-metadata"><cite>Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children [published correction appears
                                 in <em>Pediatr Infect Dis J</em>. 2001;20:421].
                                 <span class="cit-source">Pediatr Infect Dis J.</span><span class="cit-pub-date">2001</span>;<span class="cit-vol">20</span>
                                 :<span class="cit-fpage">127</span>–
                                 133</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/00006454-200102000-00002&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11224828&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000167006500001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15 in text"
                           id="ref-15">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.15"
                             data-doi="10.1097/01.inf.0000154322.38267.ce">
                           <div class="cit-metadata"><cite>Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency
                                 for influenza-infected children with asthma.
                                 <span class="cit-source">Pediatr Infect Dis J.</span><span class="cit-pub-date">2005</span>;<span class="cit-vol">24</span>
                                 :<span class="cit-fpage">225</span>–
                                 232</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/01.inf.0000154322.38267.ce&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15750458&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000227567700006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16 in text"
                           id="ref-16">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.16">
                           <div class="cit-metadata"><cite>Ijichi S, Ijichi N. Too early cure of influenza: recurrence in oseltamivir-treated children.
                                 <span class="cit-source">J Paediatr Child Health.</span><span class="cit-pub-date">2003</span>;<span class="cit-vol">39</span>
                                 :<span class="cit-fpage">480</span>–
                                 481</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=12919510&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000185088000022&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17 in text"
                           id="ref-17">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.17">
                           <div class="cit-metadata unstructured">BPCA executive summary NDA 21-087/NDA 21-246: Tamiflu capsules and for oral suspension. Available at: <a href="http://www.fda.gov/cder/foi/esum/2004/21087,21246_Tamiflu_clinical_BPCA.pdf">www.fda.gov/cder/foi/esum/2004/21087,21246_Tamiflu_clinical_BPCA.pdf</a>. Accessed September 20, 2006
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18 in text"
                           id="ref-18">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.18"
                             data-doi="10.1097/01.inf.0000164799.33635.fe">
                           <div class="cit-metadata"><cite>Okamoto S, Kamiya I, Kishida K, Shimakawa T, Fukui T, Morimoto T. Experience with oseltamivir for infants younger than 1 year
                                 old in Japan.
                                 <span class="cit-source">Pediatr Infect Dis J.</span><span class="cit-pub-date">2005</span>;<span class="cit-vol">24</span>
                                 :<span class="cit-fpage">575</span>–
                                 576</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/01.inf.0000164799.33635.fe&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15933579&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000230042900025&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19 in text"
                           id="ref-19">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.19"
                             data-doi="10.1111/j.1442-200x.2005.02088.x">
                           <div class="cit-metadata"><cite>Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection.
                                 <span class="cit-source">Pediatr Int.</span><span class="cit-pub-date">2005</span>;<span class="cit-vol">47</span>
                                 :<span class="cit-fpage">484</span></cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1111/j.1442-200x.2005.02088.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16091087&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000230888400027&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20 in text"
                           id="ref-20">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.20"
                             data-doi="10.1097/00006454-200005000-00005">
                           <div class="cit-metadata"><cite>Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five
                                 to twelve years of age: a randomized controlled trial.
                                 <span class="cit-source">Pediatr Infect Dis J.</span><span class="cit-pub-date">2000</span>;<span class="cit-vol">19</span>
                                 :<span class="cit-fpage">410</span>–
                                 417</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/00006454-200005000-00005&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10819336&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000086976100004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21 in text"
                           id="ref-21">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.21"
                             data-doi="10.1016/S0140-6736(98)10190-3">
                           <div class="cit-metadata"><cite>The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety
                                 of inhaled zanamivir in treatment of influenza A and B virus infections [published corrections appear in <em>Lancet</em>. 1999;353:504; and <em>Lancet</em>. 1999;353:1104].
                                 <span class="cit-source">Lancet.</span><span class="cit-pub-date">1998</span>;<span class="cit-vol">352</span>
                                 :<span class="cit-fpage">1877</span>–
                                 1881</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(98)10190-3&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9863784&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077544600007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.22"
                             data-doi="10.1053/jinf.1999.0602">
                           <div class="cit-metadata"><cite>Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir
                                 in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.
                                 <span class="cit-source">J Infect.</span><span class="cit-pub-date">2000</span>;<span class="cit-vol">40</span>
                                 :<span class="cit-fpage">42</span>–
                                 48</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1053/jinf.1999.0602&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10762110&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000085917600007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.23"
                             data-doi="10.ofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li>
                1086/314904">
                           <div class="cit-metadata"><cite>Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza
                                 A and B virus infections.
                                 <span class="cit-source">J Infect Dis.</span><span class="cit-pub-date">1999</span>;<span class="cit-vol">180</span>
                                 :<span class="cit-fpage">254</span>–
                                 261</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jinfdis&amp;resid=180/2/254"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24 in text"
                           id="ref-24">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.24"
                             data-doi="10.1056/NEJM199709253371302">
                           <div class="cit-metadata"><cite>Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment
                                 of influenzavirus infections. GG167 Influenza Study Group.
                                 <span class="cit-source">N Engl J Med.</span><span class="cit-pub-date">1997</span>;<span class="cit-vol">337</span>
                                 :<span class="cit-fpage">874</span>–
                                 880</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM199709253371302&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9302301&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997XX30200002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25 in text"
                           id="ref-25">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.25">
                           <div class="cit-metadata"><cite>Relenza [package insert]. Research Triangle Park, NC: GlaxoSmithKline, <span class="cit-pub-date">2006</span>. Available at: <a href="http://www.fda.gov/cder/foi/label/2006/021036s008lbl.pdf">www.fda.gov/cder/foi/label/2006/021036s008lbl.pdf</a>. Accessed September 20, 2006</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference 26 in text"
                           id="ref-26">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.26" data-doi="10.1086/381128">
                           <div class="cit-metadata"><cite>Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir
                                 treatment with or without postexposure prophylaxis.
                                 <span class="cit-source">J Infect Dis.</span><span class="cit-pub-date">2004</span>;<span class="cit-vol">189</span>
                                 :<span class="cit-fpage">440</span>–
                                 449</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jinfdis&amp;resid=189/3/440"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference 27 in text"
                           id="ref-27">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.27"
                             data-doi="10.1001/jama.285.6.748">
                           <div class="cit-metadata"><cite>Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized
                                 controlled trial.
                                 <span class="cit-source">JAMA.</span><span class="cit-pub-date">2001</span>;<span class="cit-vol">285</span>
                                 :<span class="cit-fpage">748</span>–
                                 754</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.285.6.748&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11176912&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000166817200031&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference 28 in text"
                           id="ref-28">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.28"
                             data-doi="10.1056/NEJM200011023431801">
                           <div class="cit-metadata"><cite>Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study
                                 Group.
                                 <span class="cit-source">N Engl J Med.</span><span class="cit-pub-date">2000</span>;<span class="cit-vol">343</span>
                                 :<span class="cit-fpage">1282</span>–
                                 1289</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM200011023431801&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11058672&amp;link_type=MED"
     tra">                            class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000090131600001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference 29 in text"
                           id="ref-29">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.29"
                             data-doi="10.1056/NEJMp068030">
                           <div class="cit-metadata"><cite>Hayden FG. Antiviral resistance in influenza viruses: implications for management and pandemic response.
                                 <span class="cit-source">N Engl J Med.</span><span class="cit-pub-date">2006</span>;<span class="cit-vol">354</span>
                                 :<span class="cit-fpage">785</span>–
                                 788</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMp068030&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16495389&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000235456200001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference 30 in text"
                           id="ref-30">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.30"
                             data-doi="10.1016/S0140-6736(04)16934-1">
                           <div class="cit-metadata"><cite>Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive
                                 study.
                                 <span class="cit-source">Lancet.</span><span class="cit-pub-date">2004</span>;<span class="cit-vol">364</span>
                                 :<span class="cit-fpage">759</span>–
                                 765</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(04)16934-1&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15337401&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000223569600026&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference 31 in text"
                           id="ref-31">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.31"
                             data-doi="10.1016/S0166-3542(01)00215-7">
                           <div class="cit-metadata"><cite>Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate
                                 has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
                                 <span class="cit-source">Antiviral Res.</span><span class="cit-pub-date">2002</span>;<span class="cit-vol">54</span>
                                 :<span class="cit-fpage">79</span>–
                                 88</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0166-3542(01)00215-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12062393&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000175644000002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference 32 in text"
                           id="ref-32">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.32"
                             data-doi="10.1016/S0166-3542(02)00053-0">
                           <div class="cit-metadata"><cite>Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir
                                 phosphate treatment leave virus severely compromised both in vitro and in vivo.
                                 <span class="cit-source">Antiviral Res.</span><span class="cit-pub-date">2002</span>;<span class="cit-vol">55</span>
                                 :<span class="cit-fpage">307</span>–
                                 317</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0166-3542(02)00053-0&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12103431&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000177186000005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference 33 in text"
                           id="ref-33">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.33"
                             data-doi="10.1128/AAC.49.10.4075-4084.2005">
                           <div class="cit-metadata"><cite>Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness
                                 and transmissibility.
                                 <span class="cit-source">Antimicrob Agents Chemother.</span><span class="cit-pub-date">2005</span>;<span class="cit-vol">49</span>
                                 :<span class="cit-fpage">4075</span>–
                                 4084</cite></div>
                           <diimicrob Agentv class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=aac&amp;resid=49/10/4075"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference 34 in text"
                           id="ref-34">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.34">
                           <div class="cit-metadata"><cite>Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A
                                 in adults.
                                 <span class="cit-source">Cochrane Database Syst Rev.</span><span class="cit-pub-date">2004</span>;<span class="cit-vol">(3)</span>
                                 :CD001169</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference 35 in text"
                           id="ref-35">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.35"
                             data-doi="10.1001/jama.295.8.joc60020">
                           <div class="cit-metadata"><cite>Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005–2006
                                 influenza season in the United States.
                                 <span class="cit-source">JAMA.</span><span class="cit-pub-date">2006</span>;<span class="cit-vol">295</span>
                                 :<span class="cit-fpage">891</span>–
                                 894</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.295.8.joc60020&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16456087&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000235459200021&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference 36 in text"
                           id="ref-36">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.36">
                           <div class="cit-metadata"><cite>Kitamoto O. Therapeutic effectiveness of amantadine hydrochloride in influenza A2: double blind studies.
                                 <span class="cit-source">Jpn J Tuberc Chest Dis.</span><span class="cit-pub-date">1968</span>;<span class="cit-vol">15</span>
                                 :<span class="cit-fpage">17</span>–
                                 26</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4906644&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.37">
                           <div class="cit-metadata"><cite>Kitamoto O. Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza: double-blind
                                 studies.
                                 <span class="cit-source">Jpn J Tuberc Chest Dis.</span><span class="cit-pub-date">1971</span>;<span class="cit-vol">17</span>
                                 :<span class="cit-fpage">1</span>–
                                 7</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4948478&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.38">
                           <div class="cit-metadata"><cite>Galbraith AW, Oxford JS, Schild GC, Potter CW, Watson GI. Therapeutic effect of 1-adamantanamine hydrochloride in naturally
                                 occurring influenza A2-Hong Kong infection: a controlled double-blind study.
                                 <span class="cit-source">Lancet.</span><span class="cit-pub-date">1971</span>;<span class="cit-vol">2(7716)</span>
                                 :<span class="cit-fpage">113</span>–
                                 115</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.39">
                           <div class="cit-metadata"><cite>Galbraith AW, Schild GC, Potter CW, Watson GI. The therapeutic effect of amantadine in influenza occurring during the winter
                                 of 1971–2 assessed by double-blind study.
                                 <span class="cit-source">J R Coll Gen Pract.</span><span class="cit-pub-date">1973</span>;<span class="cit-vol">23</span>
                                 :<span class="cit-fpage">34</span>–
                                 37</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4574716&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-40-1" title="View reference 40 in text"
                           id="ref-40">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.40">
                           <div class="cit-metadata"><cite>Galbraith AW. Experiences from planning and execution of a controlled therapeutic trial in new cases of epilepsy.
                                 <span class="cit-source">Acta Neurol Scand Suppl.</span><span class="cit-pub-date">1975</span>;<span class="cit-vol">60</span>
                                 :<span class="cit-fpage">75</span>–
                                 76</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=1103556&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference 41 in text"
                           id="ref-41">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.41">
                           <div class="cit-metadata"><cite>Symmetrel [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc; <span class="cit-pub-date">2003</span>. Available at: <a href="http://www.endo.com/PDF/symmetrel_pack_insert.pdf">www.endo.com/PDF/symmetrel_pack_insert.pdf</a>. Accessed September 20, 2006</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference 42 in text"
                           id="ref-42">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.42">
                           <div class="cit-metadata"><cite>Advisory Committee on Immunization Practices; Smith NM, Bresee JS, et al. Prevention and control of influenza: recommendations
                                 of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in <em>MMWR Morb Mortal Wkly Rep</em>. 2006;55:800].
                                 <span class="cit-source">MMWR Recomm Rep.</span><span class="cit-pub-date">2006</span>;<span class="cit-vol">55(RR-10)</span>
                                 :<span class="cit-fpage">1</span>–
                                 42</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-43-1" title="View reference 43 in text"
                           id="ref-43">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.43"
                             data-doi="10.1097/01.inf.0000115647.66193.45">
                           <div class="cit-metadata"><cite>Geskey JM, Thomas NJ. Amantadine penetration into cerebrospinal fluid of a child with influenza A encephalitis.
                                 <span class="cit-source">Pediatr Infect Dis J.</span><span class="cit-pub-date">2004</span>;<span class="cit-vol">23</span>
                                 :<span class="cit-fpage">270</span>–
                                 272</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/01.inf.0000115647.66193.45&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15014309&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000220317900019&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-44-1" title="View reference 44 in text"
                           id="ref-44">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.44"
                             data-doi="10.1002/jmv.1890210308">
                           <div class="cit-metadata"><cite>Thompson J, Fleet W, Lawrence E, Pierce E, Morris L, Wright P. A comparison of acetaminophen and rimantadine in the treatment
                                 of influenza A infection in children.
                                 <span class="cit-source">J Med Virol.</span><span class="cit-pub-date">1987</span>;<span class="cit-vol">21</span>
                                 :<span class="cit-fpage">249</span>–
                                 255</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/jmv.1890210308&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3549971&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1987G290400007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-45-1" title="View reference 45 in text"
                           id="ref-45">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.45">
                           <div class="cit-metadata"><cite>Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine.
                                 <span class="cit-source">Pediatrics.</span><span class="cit-pub-date">1987</span>;<span class="cit-vol">80</span>
                                 :<span class="cit-fpage">275</span>–
                                 282</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=pediatrics&amp;resid=80/2/275"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-46-1" title="View reference 46 in text"
                           id="ref-46">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.46">
                           <div class="cit-metadata"><cite>Flumadine [package insert]. St Louis, MO: Forest Pharmaceuticals Inc; <span class="cit-pub-date">2000</span>. Available at: <a href="http://www.fda.gov/cder/foi/label/2001/19650S4lbl.pdf">www.fda.gov/cder/foi/label/2001/19650S4lbl.pdf</a>. Accessed September 20, 2006</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-47-1" title="View reference 47 in text"
                           id="ref-47">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.47">
                           <div class="cit-metadata"><cite>Galbraith AW, Oxford JS, Schild GC, Watson GI. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections
                                 in the family environment: a controlled double-blind study.
                                 <span class="cit-source">Lancet.</span><span class="cit-pub-date">1969</span>;<span class="cit-vol">2(7629)</span>
                                 :<span class="cit-fpage">1026</span>–
                                 1028</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.48">
                           <div class="cit-metadata"><cite>Galbraith AW, Oxford JS, Schild GC, Watson GI. Study of 1–adamantanamine hydrochloride used prophylactically during the Hong
                                 Kong influenza epidemic in the family environment.
                                 <span class="cit-source">Bull World Health Organ.</span><span class="cit-pub-date">1969</span>;<span class="cit-vol">41</span>
                                 :<span class="cit-fpage">677</span>–
                                 682</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4908342&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1969F656300063&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li>
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-119.4.852.49">
                           <div class="cit-metadata"><cite>Schapira M, Oxford JS, Galbraith AW. A study of 1-adamantamine hydrochloride during the 1970 Hong Kong influenza epidemic.
                                 <span class="cit-source">J R Coll Gen Pract.</span><span class="cit-pub-date">1971</span>;<span class="cit-vol">21</span>
                                 :<span class="cit-fpage">695</span>–
                                 697</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4947223&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-50-1" title="View reference 50 in text"
                           id="ref-50">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.50">
                           <div class="cit-metadata"><cite>Finklea JF, Hennessy AV, Davenport FM. A field trial of amantadine prophylaxis in naturally-occurring acute respiratory illness.
                                 <span class="cit-source">Am J Epidemiol.</span><span class="cit-pub-date">1967</span>;<span class="cit-vol">85</span>
                                 :<span class="cit-fpage">403</span>–
                                 412</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=PDF&amp;journalCode=amjepid&amp;resid=85/3/403"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-51-1" title="View reference 51 in text"
                           id="ref-51">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.51"
                             data-doi="10.1001/archpedi.1986.02140210104036">
                           <div class="cit-metadata"><cite>Clover RD, Crawford SA, Abell TD, Ramsey CN Jr, Glezen WP, Couch RB. Effectiveness of rimantadine prophylaxis of children
                                 within families.
                                 <span class="cit-source">Am J Dis Child.</span><span class="cit-pub-date">1986</span>;<span class="cit-vol">140</span>
                                 :<span class="cit-fpage">706</span>–
                                 709</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/archpedi.1986.02140210104036&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3521258&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-52-1" title="View reference 52 in text"
                           id="ref-52">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.52">
                           <div class="cit-metadata"><cite>Crawford SA, Clover RD, Abell TD, Ramsey CN Jr, Glezen P, Couch RB. Rimantadine prophylaxis in children: a follow-up study.
                                 <span class="cit-source">Pediatr Infect Dis J.</span><span class="cit-pub-date">1988</span>;<span class="cit-vol">7</span>
                                 :<span class="cit-fpage">379</span>–
                                 383</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3292997&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1988N815200002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-53-1" title="View reference 53 in text"
                           id="ref-53">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.53"
                             data-doi="10.1016/j.jcv.2004.02.009">
                           <div class="cit-metadata"><cite>De Clercq E. Antiviral drugs in current clinical use.
                                 <span class="cit-source">J Clin Virol.</span><span class="cit-pub-date">2004</span>;<span class="cit-vol">30</span>
                                 :<span class="cit-fpage">115</span>–
                                 133</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.jcv.2004.02.009&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15125867&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000221715700001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-54-1" title="View reference 54 in text"
                           id="ref-54">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.54" data-doi="10.1086/375799">
                           <div class="cit-metadata"><cite>Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different
                                 mutations in amantadine-treated children with influenza.
                                 <span class="cit-source">J Infect Dis.</span><span class="cit-pub-date">2003</span>;<span class="cit-vol">188</span>
                                 :<span class="cit-fpage">57</span>–
                                 61</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jinfdis&amp;resid=188/1/57"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-55-1" title="View reference 55 in text"
                           id="ref-55">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.55">
                           <div class="cit-metadata"><cite>Centers for Disease Control and Prevention. High levels of adamantane resistance among influenza A (H3N2) viruses and interim
                                 guidelines for use of antiviral agents: United States, 2005–06 influenza season.
                                 <span class="cit-source">MMWR Morb Mortal Wkly Rep.</span><span class="cit-pub-date">2006</span>;<span class="cit-vol">55</span>
                                 :<span class="cit-fpage">44</span>–
                                 46</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=16424859&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-56-1" title="View reference 56 in text"
                           id="ref-56">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.56"
                             data-doi="10.1016/S0022-3476(94)70139-3">
                           <div class="cit-metadata"><cite>Rodriguez WJ, Hall CB, Welliver R, et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with
                                 influenza: a double-blind, multicenter, placebo-controlled trial.
                                 <span class="cit-source">J Pediatr.</span><span class="cit-pub-date">1994</span>;<span class="cit-vol">125</span>
                                 :<span class="cit-fpage">129</span>–
                                 135</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0022-3476(94)70139-3&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8021762&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1994NW31700026&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-57-1" title="View reference 57 in text"
                           id="ref-57">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.57">
                           <div class="cit-metadata"><cite>Hayden FG, Sable CA, Connor JD, Lane J. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus
                                 infection.
                                 <span class="cit-source">Antivir Ther.</span><span class="cit-pub-date">1996</span>;<span class="cit-vol">1</span>
                                 :<span class="cit-fpage">51</span>–
                                 56</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=11322259&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-58-1" title="View reference 58 in text"
                           id="ref-58">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.58">
                           <div class="cit-metadata"><cite>Hayden FG. Pandemic influenza: is an antiviral response realistic?
                                 <span class="cit-source">Pediatr Infect Dis J.</span><span class="cit-pub-date">2004</span>;<span class="cit-vol">23(11 suppl)</span>
                                 :<span class="cit-fpage">S262</span>–
                                 S269</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-59-1" title="View reference 59 in text"
                           id="ref-59">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.59"
                             data-doi="10.1098/rstb.2001.1007">
                           <div class="cit-metadata"><cite>Hayden FG. Perspectives on antiviral use during pandemic influenza.
                                 <span class="cit-source">Philos Trans R Soc Lond B Biol Sci.</span><span class="cit-pub-date">2001</span>;<span class="cit-vol">356</span>
                                 :<span class="cit-fpage">1877</span>–
                                 1884</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=royptb&amp;resid=356/1416/1877"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
               -ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract         </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-60-1" title="View reference 60 in text"
                           id="ref-60">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.60">
                           <div class="cit-metadata unstructured">World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Available
                              at: <a href="http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_10_16/en/index.html">www.who.int/csr/disease/avian_influenza/country/cases_table_2006_10_16/en/index.html</a>. Accessed October 24, 2006
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-61-1" title="View reference 61 in text"
                           id="ref-61">↵</a><div class="cit ref-cit ref-other" id="cit-119.4.852.61">
                           <div class="cit-metadata unstructured">Department of Health and Human Services. Pandemic flu Web site. Available at: <a href="http://www.pandemicflu.gov">www.pandemicflu.gov</a>. Accessed October 24, 2006
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                  </ol>
               </div>
               <ul class="copyright-statement">
                  <li class="fn" id="copyright-statement-1">Copyright © 2007 by the American Academy of Pediatrics</li>
               </ul><span class="highwire-journal-article-marker-end"></span></div><span id="related-urls"></span><div id="relmgr-related"></div>
            <div id="after_resource_related_reaffirmation"
                 class="relmgr-relation related_reaffirmation">
               <h2>Statement of reaffirmation:</h2>
               <ul class="related-list">
                  <li class="cit has-earlier-version">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">From the American Academy of Pediatrics<span class="cit-sep cit-sep-after-article-section">:</span> </span><span class="cit-title">AAP Publications Reaffirmed and Retired </span> <cite><abbr title="Pediatrics" class="site-title">Pediatrics</abbr> <span class="cit-print-date">2010<span class="cit-sep cit-sep-after-article-print-date">;</span> </span><span class="cit-vol">126<span class="cit-sep cit-sep-after-article-vol">:</span></span><span class="cit-issue">3 </span><span class="cit-pages"><span class="cit-first-page">591</span></span><span class="cit-sep cit-sep-after-article-pages">; </span><span class="cit-ahead-of-print-date"><span class="cit-sep cit-sep-before-article-ahead-of-print-date">published ahead of print </span>August 30, 2010<span class="cit-sep cit-sep-after-article-ahead-of-print-date">, </span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi">doi:</span>10.1542/peds.2010-1909 </span></cite>  
                     </div>
                     <div class="cit-extra">
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/126/3/591.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/126/3/591.full" rel="full-text">Full Text</a></li>
                           <li class="last-item"><a href="/content/126/3/591.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                        </ul>  
                     </div> 
                  </li>
               </ul>
            </div>
            <div id="after_resource_related_retirement"
                 class="relmgr-relation related_retirement">
               <h2>Statement of retirement:</h2>
               <ul class="related-list">
                  <li class="cit has-earlier-version e2">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">From the American Academy of Pediatrics<span class="cit-sep cit-sep-after-article-section">:</span> </span><span class="cit-title"><span class="cit-series-title">Statement of Endorsement<span class="cit-sep cit-sep-after-article-series-title">:</span> </span>AAP Publications Reaffirmed and Retired </span> <cite><abbr title="Pediatrics" class="site-title">Pediatrics</abbr> <span class="cit-print-date">2014<span class="cit-sep cit-sep-after-article-print-date">;</span> </span><span class="cit-vol">133<span class="cit-sep cit-sep-after-article-vol">:</span></span><span class="cit-issue">5 </span><span class="cit-pages"><span class="cit-first-page">e1479</span><span class="cit-sep">-</span><span class="cit-last-page">e1480</span></span><span class="cit-sep cit-sep-after-article-pages">; </span><span class="cit-ahead-of-print-date"><span class="cit-sep cit-sep-before-article-ahead-of-print-date">published ahead of print </span>April 28, 2014<span class="cit-sep cit-sep-after-article-ahead-of-print-date">, </span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi">doi:</span>10.1542/peds.2014-0452 </span></cite>  
                     </div>
                     <div class="cit-extra">
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/133/5/e1479.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/133/5/e1479.full" rel="full-text">Full Text</a></li>
                           <li class="last-item"><a href="/content/133/5/e1479.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                        </ul>  
                     </div> 
                  </li>
               </ul>
            </div>
         </div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/119/4/846.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/119/4/861.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/119/4.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              
                              		
                              
                              <cite>
           <ol>
                        <li>
                           <div id="slugline">
                              
                              
                              		
                              
                              <c                              	    <abbr title="Pediatrics" class="slug-jnl-abbrev">
                                    Pediatrics</abbr>
                                 	    <span class="slug-vol">
                                    Vol. 119 
                                    </span><span class="slug-issue">
                                    No. 4 
                                    </span><span class="slug-pub-date" itemprop="datePublished">
                                    April 1, 2007 
                                    </span><br /><span class="slug-pages">
                                    pp. 852
                                    -860
                                    </span><br /><span title="10.1542/peds.2007-0224" class="slug-doi">
                                    
                                    (doi:
                                    
                                    10.1542/peds.2007-0224)
                                    </span>
                                 </cite>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/119/4/852.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link primary"><span class="variant-indicator">» <span>Full Text</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link primary"><a href="/content/119/4/852.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Article Type</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=FROM+THE+AMERICAN+ACADEMY+OF+PEDIATRICS&amp;sortspec=date&amp;submit=Submit">FROM THE AMERICAN ACADEMY OF PEDIATRICS</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="mail-a-friend-link icon-link"><a href="/email?gca=pediatrics%3B119%2F4%2F852&amp;current-view-path=/content/119/4/852.full">
                              Email this article to a friend
                              </a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=pediatrics%3B119%2F4%2F852&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://pediatrics.aappublications.org/content/119/4/852.full">Alert me when this article is cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=119/4/852&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://pediatrics.aappublications.org/content/119/4/852.full">Alert me if a correction is posted</a></li>
                        <li class="alert-link eletter-alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=eletter&amp;addAlert=eletter&amp;eletter_criteria_value=119/4/852&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://pediatrics.aappublications.org/content/119/4/852.full">Alert me when eletters are published</a></li>
                        <li class="similar-link"><a href="/search?qbe=pediatrics%3B119%2F4%2F852&amp;citation=%20119%20%284%29:%20852&amp;submit=yes">Similar articles in this journal</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=pediatrics%3B119%2F4%2F852&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=17403862&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=pediatrics%3B119%2F4%2F852">Add to My File Cabinet
                              </a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=pediatrics%3B119%2F4%2F852">Download to citation manager</a></li>
                        <li class="copyright-link icon-link"><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=AAP&amp;publication=pediatrics&amp;title=Antiviral Therapy and Prophylaxis for Influenza in Children&amp;publicationDate=April 2007&amp;author=Committee on Infectious Diseases&amp;startPage=852&amp;contentID=10.1542/peds.2007-0224&amp;orderBeanReset=true&amp;endPage=860&amp;volumeNum=119&amp;issueNum=4"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-letter-cit">
                     <h4 class="cb-section-header"><span>eLetters</span></h4>
                     <ol>
                        <li><span class="eletters-no-responses-published">No eLetters published</span></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/119/4/852.full?cited-by=yes&amp;legid=pediatrics;119/4/852#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/external-ref?access_num=http://pediatrics.aappublications.org/content/119/4/852.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://pediatrics.aappublications.org/content/119/4/852.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=17403862&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li>
                           <div id="cb-entrez-links-placeholder"><a href="/entrez-links/17403862"></a></div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="/cgi/collection/infectious_diseases_sub">Infectious Diseases</a></li>
                        <li><a href="/cgi/collection/influenza_sub">Influenza</a></li>
                        <li><a href="/cgi/collection/vaccine:immunization_sub">Vaccine/Immunization</a></li>
                        <li><a href="/content/119/4/852.full?related-urls=yes&amp;legid=pediatrics;119/4/852#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed soc-links icon-link"
                       id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Social Bookmarking</span></h4>
                     <ol>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://pediatrics.aappublications.org/cgi/content/long/119/4/852&amp;title=Antiviral%20Therapy%20and%20Prophylaxis%20for%20Influenza%20in%20Children+--+%20119%20%284%29%3A%20852+--+&amp;doi=10.1542/peds.2007-0224&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://pediatrics.aappublications.org/cgi/content/long/119/4/852&amp;title=Antiviral%20Therapy%20and%20Prophylaxis%20for%20Influenza%20in%20Children+--+%20119%20%284%29%3A%20852+--+&amp;doi=10.1542/peds.2007-0224&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-digg"><a href="/external-ref?tag_url=http://pediatrics.aappublications.org/cgi/content/long/119/4/852&amp;title=Antiviral%20Therapy%20and%20Prophylaxis%20for%20Influenza%20in%20Children+--+%20119%20%284%29%3A%20852+--+&amp;doi=10.1542/peds.2007-0224&amp;link_type=DIGG"><img src="/shared/img/common/social-bookmarking/digg.gif" alt="Add to Digg"
                                            title="Digg" /></a><span class="soc-bm-link-text">Digg</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://pediatrics.aappublications.org/cgi/content/short/119/4/852&amp;title=Antiviral%20Therapy%20and%20Prophylaxis%20for%20Influenza%20in%20Children+--+%20119%20%284%29%3A%20852+--+&amp;doi=10.1542/peds.2007-0224&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://pediatrics.aappublications.org/cgi/content/long/119/4/852&amp;title=Antiviral%20Therapy%20and%20Prophylaxis%20for%20Influenza%20in%20Children+--+%20119%20%284%29%3A%20852+--+&amp;doi=10.1542/peds.2007-0224&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-reddit"><a href="/external-ref?tag_url=http://pediatrics.aappublications.org/cgi/content/long/119/4/852&amp;title=Antiviral%20Therapy%20and%20Prophylaxis%20for%20Influenza%20in%20Children+--+%20119%20%284%29%3A%20852+--+&amp;doi=10.1542/peds.2007-0224&amp;link_type=REDDIT"><img src="/shared/img/common/social-bookmarking/reddit.gif" alt="Add to Reddit"
                                            title="Reddit" /></a><span class="soc-bm-link-text">Reddit</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://pediatrics.aappublications.org/cgi/content/long/119/4/852&amp;title=Antiviral%20Therapy%20and%20Prophylaxis%20for%20Influenza%20in%20Children+--+%20119%20%284%29%3A%20852+--+&amp;doi=10.1542/peds.2007-0224&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span><iv>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Ar/h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-1">INTRODUCTION</a></li>
                        <li><a href="#sec-2">ANTIVIRAL DRUGS FOR EPIDEMIC AND PANDEMIC INFLUENZA</a></li>
                        <li><a href="#sec-16">INDICATIONS FOR THERAPY AND PROPHYLAXIS</a></li>
                        <li><a href="#sec-19">ANTIVIRAL THERAPY IN PANDEMIC INFLUENZA</a></li>
                        <li><a href="#sec-20">Committee on Infectious Diseases, 2006–2007</a></li>
                        <li><a href="#sec-21">Liaisons</a></li>
                        <li><a href="#sec-22">Ex Officio</a></li>
                        <li><a href="#sec-23">Consultant</a></li>
                        <li><a href="#sec-24">Staff</a></li>
                        <li><a href="#sec-25">APPENDIX: INFANTS AND CHILDREN AT HIGH RISK OF COMPLICATIONS FROM INFLUENZA INCLUDE THOSE WITH:</a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">REFERENCES</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            <div class="future-space sb-div"></div>
            <div class="future-link">
               <a id="future-link" href="/content/future">
                  Papers in Press
                  </a>
               
            </div>
            
         </div>
         <div id="col-3">
            
            
            
            <div id="sidebar">
               
               <ul>
                  <li>
                     
                     <div id="search">
                        
                        <form method="get" enctype="application/x-www-form-urlencoded" id="site_search"
                              action="/search"><input type="text" id="header-qs-input" name="fulltext" title="Search Pediatrics"
                                  value="" /><input type="hidden" name="submit" value="yes" /><div class="search-btn">
                              <input type="image" id="header-qs-search-go" alt="search"
                                     src="/local/img/aap_search.jpg"
                                     value="go" />
                              
                           </div>
                           <div class="search-txt">
                              <a id="adv-search" href="/search">Advanced Search</a>
                              
                           </div>
                        </form>
                        
                     </div>
                     
                  </li>
               </ul>
               
               <h3>My Pediatrics</h3>
               
               <ul>
                  <li>
                     <a href="/cgi/login">Log In</a>
                     
                  </li>
                  <li>
                     <a href="http://shop.aap.org/product-list/?q=PED">Subscribe/Renew</a>
                     
                  </li>
                  <li>
                     <a href="/site/misc/myaccount.xhtml">Manage My Account</a>
                     
                  </li>
                  <li>
                     <a href="/cgi/folders">File Cabinet</a>
                     
                  </li>
                  <li>
                     <a href="/rss">RSS Feeds</a>
                     
                  </li>
                  <li>
                     <a href="/cgi/alerts/etoc">eAlerts</a>
                     
                  </li>
                  <li>
                     <a href="/site/misc/new_features.xhtml">New Features</a>
                     
                  </li>
               </ul>
               
            </div>
            
            <ul class="tower-ads-container">
               <li class="position-top">
                  <a class="tower-ads-word" href="/site/misc/ad_disclaimer.xhtml">Advertising Disclaimer</a>          
                  
               </li>
               <li class="position-ad">
                  <script language="JavaScript" type="text/javascript">
                    OAS_AD('Right');
                </script>
                  </li>
            </ul>
            
            
            
         </div>
         
         <div id="footer">
            
            <ul id="footer_logos">
               <li class="align_left">
                  <a href="http://www.dcprinciples.org">
                     <img src="/publisher/img/logo_free_access_science.jpg" />
                     </a>
                  
               </li>
               <li class="align_center">
                  <a href="http://www.aap.org">
                     <img src="/publisher/img/logo_aap.jpg" />
                     </a>
                  
               </li>
               <li class="align_right">
                  <a href="http://highwire.stanford.edu/">
                     <img src="/publisher/img/logo_hwp.jpg" />
                     </a>
                  
               </li>
            </ul>
            
            <p>
               <strong>CONTENT:</strong>  <a href="http://pediatrics.aappublications.org/">Home</a>  |   <a href="http://pediatrics.aappublications.org/site/misc/about.xhtml">About the Journal</a>  |   <a href="http://shop.aap.org/product-list/?q=PED">Subscribe/Renew</a>
               
            </p>
            
            <p>
               <strong>RESOURCES:</strong>  <a href="http://aapgrandrounds.aappublications.org/">AAP Grand Rounds</a>  |   <a href="http://www.aapnews.org/">AAP News</a>  |   <a href="http://www.hospitalpediatrics.org/">Hospital Pediatrics</a>  |   <a href="http://www.aap.org/livecme/">Live CME Events</a>  |   <a href="http://www.neoreviews.org/">NeoReviews</a>  |   <a href="http://www.pediatrics.org/">Pediatrics</a>  |   <a href="http://pedsinreview.aappublications.org/">Pediatrics in Review</a>  |   <a href="http://www.pedjobs.org">PedJobs</a>  |   <a href="http://www.pedialink.org">PediaLink</a>  
            </p>
            
            <p>
               <strong>PREP:</strong>  <a href="http://www.prepaudio.org">PREP Audio</a>  |   <a href="http://aap.org/prepsubs/">PREP Subspecialties  |  </a>
               <a href="http://eweb.aap.org/prepc">PREP The Curriculum</a>
               
            </p>
            
            <p>
               <strong>AAP:</strong>  <a href="http://www.aap.org">AAP.org</a>  |   <a href="/cgi/feedback">Contact AAP</a>  |   <a href="http://www.aap.org/about/privacystmt.htm">Privacy Statement</a>  
            </p>
            
            <div class="copyright" id="copyright">
               
               <p>2013 © Copyright American Academy of Pediatrics. All rights reserved.<br />
                  American Academy of Pediatrics, 141 Northwest Point Blvd., Elk Grove Village, IL, 847-434-4000
               </p>
               
               <p id="international_access">
                  <a href="/help/slow.dtl">Click here for faster international access</a>
                  
               </p>
               
            </div>
            
         </div>
         <script type="text/javascript">
piAId = '50222';
piCId = '4524';

(function() {
	function async_load(){
		var s = document.createElement('script'); s.type = 'text/javascript';
		s.src = ('https:' == document.location.protocol ? 'https://pi' : 'http://cdn') + '.pardot.com/pd.js';
		var c = document.getElementsByTagName('script')[0]; c.parentNode.insertBefore(s, c);
	}
	if(window.attachEvent) { window.attachEvent('onload', async_load); }
	else { window.addEventListener('load', async_load, false); }
})();
</script>
         <div class="block-2 sb-div"></div><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-2459237-1");
        pageTracker._trackPageview();
        } catch(err) {}
        </script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-9");
        pageTracker._setDomainName(".aappublications.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script><script type="text/javascript">
	(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
		(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
		m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	})(window,document,'script','//www.google-analytics.com/analytics.js','ga');

	ga('create', 'UA-3973671-2', '.aappublications.org');
	ga('send', 'pageview', {
	
        'dimension1': 'is_institutional_user',
    
	});
	</script></div>
   </body>
</html>
	})(windo